Please login to the form below

Not currently logged in
Email:
Password:

vaccine trials

This page shows the latest vaccine trials news and features for those working in and with pharma, biotech and healthcare.

Valneva set to begin commercial manufacturing of COVID-19 vaccine within days

Valneva set to begin commercial manufacturing of COVID-19 vaccine within days

In December 2020, Valneva announced that it had launched phase 1/2 trials of its potential COVID-19 vaccine across four National Institute for Health Research (NIHR) testing sites in the ... VLA2001 uses the same manufacturing platform used by Valneva to

Latest news

More from news
Approximately 0 fully matching, plus 116 partially matching documents found.

Latest Intelligence

  • How will COVID-19 affect uptake of vaccinations against other diseases? How will COVID-19 affect uptake of vaccinations against other diseases?

    Not just for the COVID-19 programmes, but for every other vaccine made these days. ... no large-scale clinical trials having been completed, caused widespread concern among the scientific community.

  • Multilingual remote conferencing and interpreting platforms in the era of COVID-19 Multilingual remote conferencing and interpreting platforms in the era of COVID-19

    In April this year there were 650 groups around the world carrying out 460 different coronavirus vaccine trials on hundreds of thousands of individuals from different nationalities. ... will lead to even greater engagement with medical and clinical

  • Developing a COVID-19 vaccine Developing a COVID-19 vaccine

    Pharma giant Johnson &Johnson is also at the forefront of developing a COVID-19 vaccine, having said it plans to start clinical trials of its lead candidate in September. ... Researchers from Oxford University have also said they plan to start clinical

  • Deal Watch September 2016 Deal Watch September 2016

    Celgene will be responsible for development costs for all indications from phase II clinical trials and beyond. ... Moderna Therapeutics has received $8m of the grant to fund early-stage trials of the vaccine and plans to submit an investigational new

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Andrew Gengos joins ImmunoCellular as CEO Andrew Gengos joins ImmunoCellular as CEO

    Will lead company as it initiates phase II trials investigating brain tumour vaccine. ... Gengos joins at an important time for ImmunoCellular, with the company having recently commenced a phase II trial investigating its lead product candidate ICT-107,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Is the world ready for a COVID-19 vaccine? Is the world ready for a COVID-19 vaccine?

    Another, and perhaps grander, challenge is one of global vaccine equity and reducing inequalities in access. ... As companies continue to publish positive results from vaccine trials, it will be critical for the pharmaceutical sector, advocacy

  • Diversity in clinical trials needs to extend beyond COVID-19 vaccine trials Diversity in clinical trials needs to extend beyond COVID-19 vaccine trials

    trials. For example:. Religious and cultural barriers that are more prominent among ethnic minorities. ... So, these are the reasons why diversity needs to improve in clinical trials.

  • Why Facebook is not the solution to inclusive patient recruitment Why Facebook is not the solution to inclusive patient recruitment

    With so many clinical trials underway to find an effective vaccine for COVID-19, the competition is rising. ... More and more organisations will be looking to recruit healthy volunteers, while ensuring inclusion and diversity in clinical trials, to

  • Are patient recruitment and retention rates rising or falling? Are patient recruitment and retention rates rising or falling?

    Both North American and Asia/Pacific trials achieved an activation rate of more than 85%. ... Vaccine trials experienced a 12.3% dropout rate in 2019. Cardiovascular and rare disease trials fared best, with rates of 7% and 6.5% respectively.

  • COUCH Health COUCH Health

    Diversity in clinical trials needs to extend beyond COVID-19 vaccine trials. ... With so many clinical trials underway to find an effective vaccine for COVID-19, the competition is rising.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics